Alectinib Induced Regression of Renal and Hepatic Cysts Caused by Crizotinib

BACKGROUND: Crizotinib is the first tyrosine kinase inhibitor approved for the treatment of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC). An increased incidence of renal cysts has been described during the crizotinib treatment. CASE PRESENTATION: We herein report th...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Int Med Case Rep J
Main Authors: Di Marino, Pietro, Mannetta, Gianluca, Carella, Consiglia, Grassadonia, Antonino, Tinari, Nicola, Natoli, Clara, De Tursi, Michele
Formato: Artigo
Idioma:Inglês
Publicado em: Dove 2020
Assuntos:
Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7083626/
https://ncbi.nlm.nih.gov/pubmed/32214855
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IMCRJ.S229080
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados